Brief Introduction

Since the founding of our company in 2004, Medicilon (stock code : 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, we keep improving our service system in biotechnology and pharmaceutical research. Our service now spans cross medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.

In the past 15 years, we have worked with more than 500 clients worldwide on their scientific research, among which more than 60 cases successfully gained certifications for Phase I clinical trials. Our research team is capable of, but not limited to the medicinal research of small molecule chemicals, antibody, PROTAC, ADC, CAR-T, etc.

Medicilon is fully accredited by the International Laboratory Animal Assessment and Accreditation (AAALAC) and in compliance with the US Food and Drug Administration(US FDA)’s Good Laboratory Practice(GLP). The standard of laboratories is certified by the National Medical Products Administration (NMPA) for GLP compliance.

Company Overview

Full name Shanghai Medicilon Inc.
Abbreviations Medicilon
Code 688202
Founded 2004-2-2
Listing 2019-11-5
Domicile Shanghai
STAR Theme Biomedicine
CSRCSector Scientific research and technical service
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share 1.31 0.90 1.00
R&D expenditure as a % of operating revenue 5.08% 4.44% 4.00%
Operating Revenue 324.94 249.27 232.32
Net Income 62.43 42.68 44.43

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 324.94 249.27 232.32
Operating Costs 262.81 209.90 187.72
Operating Income 71.29 48.77 44.61
Pretax Income 71.58 49.34 51.55
Income Tax 9.15 6.66 7.12
Net Income 62.43 42.68 44.43

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 272.97 243.49 241.16
Non-current Assets-Total 204.73 149.16 105.85
Total Assets 477.70 392.65 347.01
Current Liabilities-Total 109.99 85.05 82.45
Non-current Liabilities-Total 14.39 16.71 16.35
Total Liabilities 124.38 101.76 98.81
Stockholder's Equity
Share Capital 238.99 238.99 238.99
Retained Profits 108.74 47.96 6.35
Minority Interests 5.60 3.94 2.88
Total Owners' Equity 353.32 290.89 248.21

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 71.11 74.70 34.13
Net Cash Flows-Investing -64.37 -58.91 -31.39
Net Cash Flows-Financing 0 0 116.19

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
陈金章 9.72 15.68%
陈建煌 6.14 9.91%
陈春来 4.96 8.00%
林长青 3.72 6.00%
陈国兴 3.31 5.34%
王国林 2.85 4.59%
深圳人合资本管理有限公司-新余人合厚丰投资合伙企业(有限合伙) 2.06 3.33%
CHEN CHUN-LIN 2.03 3.28%
上海美迪西生物医药股份有限公司未确认持有人证券专用账户 1.81 2.91%
广发证券资管-工商银行-广发原驰.美迪西战略配售1号集合资产管理计划 1.55 2.50%
As of November 4, 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.